Interpace Biosciences
Interpace Biosciences Posts 6 Percent Revenue Increase in Q1
The company said that it experienced improved reimbursement rates and clinical services volume for its thyroid cancer tests compared to Q1 of last year.
Interpace Biosciences, Miroculus, Twist Bioscience Partner to Automate NGS Library Prep in Cancer Dx
The three companies join forces to automate sample preparation for genetic testing of endocrine and GI cancers using digital microfluidics technology.
Interpace Biosciences Reports 14 Percent Increase in Q4 Revenues
The revenue gains came from increased reimbursement rates and clinical services volume for the company's thyroid cancer tests.
Interpace Biosciences Says CMS to Cover Thyroid Tests, Reversing Earlier Decision
CMS previously said it would no longer reimburse for the ThyGeNext and ThyraMir tests when the tests are billed together.
CMS No Longer Reimbursing Interpace Bio Thyroid Tests; Firm's Rights Offering Terminated
CMS has issued a new billing policy and will no longer reimburse for the use of Interpace's ThyGeNext and ThyraMir thyroid cancer tests under certain conditions.
Jan 13, 2022
Interpace Commences $30M Rights Offering
Nov 11, 2021
Interpace Biosciences Q3 Revenues Rise 15 Percent
Aug 11, 2021
Interpace Biosciences Q2 Revenues More Than Double
May 12, 2021
Interpace Biosciences Q1 Revenues Up 8 Percent
Jan 20, 2021
Interpace Bio Q3 Revenues Rise 6 Percent
Oct 20, 2020
Interpace Biosciences Q2 Revenues Decline 14 Percent
Jun 26, 2020